Bevacizumab for the management of diabetic macular edema

doi:10.4239/wjd.v4.i2.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7798)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

531

HTML

4822

Figures (1-5)

352

Sum=5705

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1119

Download

966

Sum=2085

Apr 15, 2013 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Diabetes. Apr 15, 2013; 4(2): 19-26
Published online Apr 15, 2013. doi: 10.4239/wjd.v4.i2.19

Full Size Figure Download Figure

Figure 4 Cost per injection of ranibizumab (LucentisTM Genentech, United States), in the treatment of diabetic macular edema, compared with the cost per injection of bevacizumab (Avastin, Roche, United States). The cost is, in average, 20-fold higher in for treatment with ranibizumab than bevacizumab. Depending on the country, this difference may vary from 20× to 50×.

Citation: Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013; 4(2): 19-26
URL: https://www.wjgnet.com/1948-9358/full/v4/i2/19.htm
DOI: https://dx.doi.org/10.4239/wjd.v4.i2.19